NCT04951804Recruiting
EUS-CPN With and Without Bupivacaine
A Randomized Controlled Trial of Endoscopic Ultrasound Guided Celiac Plexus Neurolysis (EUS-CPN) With and Without Bupivacaine
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
Endoscopic ultrasound (EUS) allows EUS-guided trans gastric injection of absolute alcohol around the base of the celiac plexus (celiac plexus neurolysis (EUS-CPN)), to help alleviate pain associated with pancreatic cancer. It is standard procedure to inject bupivacaine immediately before injecting absolute alcohol, to theoretically prevent pain that may occur during and after the procedure. However, there are no data showing whether bupivacaine injection has any real influence on intra-procedural, immediate post-procedural, or long-term pain control. The injection of bupivacaine before the alcohol may have no effect, a synergistic effect, or an antagonistic effect, by diluting the alcohol, and reducing its neurolytic capacity. Inadvertent intravascular injection of bupivacaine may also cause irreversible cardiac arrhythmias and death. The investigators therefore propose a randomized clinical trial to determine whether the exclusion of bupivacaine during EUS-guided CPN improves outcomes, or not.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- First submitted
- 9 Jun 2021
- Start date
- 7 Oct 2021
- Primary completion date
- Sept 2029
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Diseases
- Pancreatic cancer
- NCT number
- NCT04951804
What you commit to
- Study type: Interventional
- Planned participants: 180
- From 7 Oct 2021 to the primary completion date, Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Allergy to bupivacaine
Who the study is looking for
- Malignant-appearing pancreatic mass, or proven pancreatic cancer involving the pancreatic genu, body, or tail
- Any level of abdominal or back pain considered to be potentially related to the mass:
- New onset pain (\<3 months)
- Constant
- Centrally located
- With or without irradiation to the back
- No obvious other source of pain based on history and physical examination by the attending endosonographer
- No possibility of surgical management
- Signed, informed consent
- Celiac axis accessible for bilateral neurolysis at EUS.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre de recherche du Centre hospitalier de l'Université de Montréal Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.